Cargando…
The effect of continuing versus withholding angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers on mortality and major adverse cardiovascular events in hypertensive patients undergoing elective non-cardiac surgery: study protocol for a multi-centric open-label randomised controlled trial
BACKGROUND: Angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers (ARBs) are commonly prescribed to patients with hypertension. These drugs are cardioprotective in addition to their blood pressure-lowering effects. However, it is debatable whether hypertensive patients who p...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9386985/ https://www.ncbi.nlm.nih.gov/pubmed/35978368 http://dx.doi.org/10.1186/s13063-022-06616-y |
_version_ | 1784769929598205952 |
---|---|
author | Misra, Satyajeet Parida, Satyen Sahajanandan, Raj Behera, Bikram Kishore Senthilnathan, Muthapillai Mariappan, Ramamani Chandy, Tony Thomson |
author_facet | Misra, Satyajeet Parida, Satyen Sahajanandan, Raj Behera, Bikram Kishore Senthilnathan, Muthapillai Mariappan, Ramamani Chandy, Tony Thomson |
author_sort | Misra, Satyajeet |
collection | PubMed |
description | BACKGROUND: Angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers (ARBs) are commonly prescribed to patients with hypertension. These drugs are cardioprotective in addition to their blood pressure-lowering effects. However, it is debatable whether hypertensive patients who present for non-cardiac surgery should continue or discontinue these drugs preoperatively. Continuing the drugs entails the risk of perioperative refractory hypotension and/or angioneurotic oedema, while discontinuing the drugs entails the risk of rebound hypertension and myocardial ischaemia. The aim of this study is to evaluate the effect of continuation vs withholding of ACEIs/ARBs on mortality and other major outcomes in hypertensive patients undergoing elective non-cardiac surgery. METHODS: The continuing vs withholding of ACEIs/ARBs in patients undergoing non-cardiac surgery is a prospective, multi-centric, open-label randomised controlled trial. Two thousand one hundred hypertensive patients receiving ACEIs/ARBs and planned for elective non-cardiac surgery will be enrolled. They will be randomised to either continue the ACEIs/ARBs including on the day of surgery (group A) or to withhold it 24–36 h before surgery (group B). The primary endpoint will be the difference in the composite outcome of all-cause in-hospital/30-day mortality and major adverse cardiovascular and non-cardiovascular events. Secondary endpoints will be to evaluate the differences in perioperative hypotension, angioneurotic oedema, myocardial injury, ICU and hospital stay. The impact of the continuation vs withholding of the ACEIs/ARBs on the incidence of case cancellation will also be studied. DISCUSSION: The results of this trial should provide sufficient evidence on whether to continue or withhold ACEIs/ARBs before major non-cardiac surgery. TRIAL REGISTRATION: Clinical Trials Registry of India CTRI/2021/01/030199. Registered on 4 January 2021 SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13063-022-06616-y. |
format | Online Article Text |
id | pubmed-9386985 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-93869852022-08-19 The effect of continuing versus withholding angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers on mortality and major adverse cardiovascular events in hypertensive patients undergoing elective non-cardiac surgery: study protocol for a multi-centric open-label randomised controlled trial Misra, Satyajeet Parida, Satyen Sahajanandan, Raj Behera, Bikram Kishore Senthilnathan, Muthapillai Mariappan, Ramamani Chandy, Tony Thomson Trials Study Protocol BACKGROUND: Angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers (ARBs) are commonly prescribed to patients with hypertension. These drugs are cardioprotective in addition to their blood pressure-lowering effects. However, it is debatable whether hypertensive patients who present for non-cardiac surgery should continue or discontinue these drugs preoperatively. Continuing the drugs entails the risk of perioperative refractory hypotension and/or angioneurotic oedema, while discontinuing the drugs entails the risk of rebound hypertension and myocardial ischaemia. The aim of this study is to evaluate the effect of continuation vs withholding of ACEIs/ARBs on mortality and other major outcomes in hypertensive patients undergoing elective non-cardiac surgery. METHODS: The continuing vs withholding of ACEIs/ARBs in patients undergoing non-cardiac surgery is a prospective, multi-centric, open-label randomised controlled trial. Two thousand one hundred hypertensive patients receiving ACEIs/ARBs and planned for elective non-cardiac surgery will be enrolled. They will be randomised to either continue the ACEIs/ARBs including on the day of surgery (group A) or to withhold it 24–36 h before surgery (group B). The primary endpoint will be the difference in the composite outcome of all-cause in-hospital/30-day mortality and major adverse cardiovascular and non-cardiovascular events. Secondary endpoints will be to evaluate the differences in perioperative hypotension, angioneurotic oedema, myocardial injury, ICU and hospital stay. The impact of the continuation vs withholding of the ACEIs/ARBs on the incidence of case cancellation will also be studied. DISCUSSION: The results of this trial should provide sufficient evidence on whether to continue or withhold ACEIs/ARBs before major non-cardiac surgery. TRIAL REGISTRATION: Clinical Trials Registry of India CTRI/2021/01/030199. Registered on 4 January 2021 SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13063-022-06616-y. BioMed Central 2022-08-17 /pmc/articles/PMC9386985/ /pubmed/35978368 http://dx.doi.org/10.1186/s13063-022-06616-y Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Study Protocol Misra, Satyajeet Parida, Satyen Sahajanandan, Raj Behera, Bikram Kishore Senthilnathan, Muthapillai Mariappan, Ramamani Chandy, Tony Thomson The effect of continuing versus withholding angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers on mortality and major adverse cardiovascular events in hypertensive patients undergoing elective non-cardiac surgery: study protocol for a multi-centric open-label randomised controlled trial |
title | The effect of continuing versus withholding angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers on mortality and major adverse cardiovascular events in hypertensive patients undergoing elective non-cardiac surgery: study protocol for a multi-centric open-label randomised controlled trial |
title_full | The effect of continuing versus withholding angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers on mortality and major adverse cardiovascular events in hypertensive patients undergoing elective non-cardiac surgery: study protocol for a multi-centric open-label randomised controlled trial |
title_fullStr | The effect of continuing versus withholding angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers on mortality and major adverse cardiovascular events in hypertensive patients undergoing elective non-cardiac surgery: study protocol for a multi-centric open-label randomised controlled trial |
title_full_unstemmed | The effect of continuing versus withholding angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers on mortality and major adverse cardiovascular events in hypertensive patients undergoing elective non-cardiac surgery: study protocol for a multi-centric open-label randomised controlled trial |
title_short | The effect of continuing versus withholding angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers on mortality and major adverse cardiovascular events in hypertensive patients undergoing elective non-cardiac surgery: study protocol for a multi-centric open-label randomised controlled trial |
title_sort | effect of continuing versus withholding angiotensin-converting enzyme inhibitors/angiotensin ii receptor blockers on mortality and major adverse cardiovascular events in hypertensive patients undergoing elective non-cardiac surgery: study protocol for a multi-centric open-label randomised controlled trial |
topic | Study Protocol |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9386985/ https://www.ncbi.nlm.nih.gov/pubmed/35978368 http://dx.doi.org/10.1186/s13063-022-06616-y |
work_keys_str_mv | AT misrasatyajeet theeffectofcontinuingversuswithholdingangiotensinconvertingenzymeinhibitorsangiotensiniireceptorblockersonmortalityandmajoradversecardiovasculareventsinhypertensivepatientsundergoingelectivenoncardiacsurgerystudyprotocolforamulticentricopenlabelrandomised AT paridasatyen theeffectofcontinuingversuswithholdingangiotensinconvertingenzymeinhibitorsangiotensiniireceptorblockersonmortalityandmajoradversecardiovasculareventsinhypertensivepatientsundergoingelectivenoncardiacsurgerystudyprotocolforamulticentricopenlabelrandomised AT sahajanandanraj theeffectofcontinuingversuswithholdingangiotensinconvertingenzymeinhibitorsangiotensiniireceptorblockersonmortalityandmajoradversecardiovasculareventsinhypertensivepatientsundergoingelectivenoncardiacsurgerystudyprotocolforamulticentricopenlabelrandomised AT beherabikramkishore theeffectofcontinuingversuswithholdingangiotensinconvertingenzymeinhibitorsangiotensiniireceptorblockersonmortalityandmajoradversecardiovasculareventsinhypertensivepatientsundergoingelectivenoncardiacsurgerystudyprotocolforamulticentricopenlabelrandomised AT senthilnathanmuthapillai theeffectofcontinuingversuswithholdingangiotensinconvertingenzymeinhibitorsangiotensiniireceptorblockersonmortalityandmajoradversecardiovasculareventsinhypertensivepatientsundergoingelectivenoncardiacsurgerystudyprotocolforamulticentricopenlabelrandomised AT mariappanramamani theeffectofcontinuingversuswithholdingangiotensinconvertingenzymeinhibitorsangiotensiniireceptorblockersonmortalityandmajoradversecardiovasculareventsinhypertensivepatientsundergoingelectivenoncardiacsurgerystudyprotocolforamulticentricopenlabelrandomised AT chandytonythomson theeffectofcontinuingversuswithholdingangiotensinconvertingenzymeinhibitorsangiotensiniireceptorblockersonmortalityandmajoradversecardiovasculareventsinhypertensivepatientsundergoingelectivenoncardiacsurgerystudyprotocolforamulticentricopenlabelrandomised AT theeffectofcontinuingversuswithholdingangiotensinconvertingenzymeinhibitorsangiotensiniireceptorblockersonmortalityandmajoradversecardiovasculareventsinhypertensivepatientsundergoingelectivenoncardiacsurgerystudyprotocolforamulticentricopenlabelrandomised AT misrasatyajeet effectofcontinuingversuswithholdingangiotensinconvertingenzymeinhibitorsangiotensiniireceptorblockersonmortalityandmajoradversecardiovasculareventsinhypertensivepatientsundergoingelectivenoncardiacsurgerystudyprotocolforamulticentricopenlabelrandomisedcon AT paridasatyen effectofcontinuingversuswithholdingangiotensinconvertingenzymeinhibitorsangiotensiniireceptorblockersonmortalityandmajoradversecardiovasculareventsinhypertensivepatientsundergoingelectivenoncardiacsurgerystudyprotocolforamulticentricopenlabelrandomisedcon AT sahajanandanraj effectofcontinuingversuswithholdingangiotensinconvertingenzymeinhibitorsangiotensiniireceptorblockersonmortalityandmajoradversecardiovasculareventsinhypertensivepatientsundergoingelectivenoncardiacsurgerystudyprotocolforamulticentricopenlabelrandomisedcon AT beherabikramkishore effectofcontinuingversuswithholdingangiotensinconvertingenzymeinhibitorsangiotensiniireceptorblockersonmortalityandmajoradversecardiovasculareventsinhypertensivepatientsundergoingelectivenoncardiacsurgerystudyprotocolforamulticentricopenlabelrandomisedcon AT senthilnathanmuthapillai effectofcontinuingversuswithholdingangiotensinconvertingenzymeinhibitorsangiotensiniireceptorblockersonmortalityandmajoradversecardiovasculareventsinhypertensivepatientsundergoingelectivenoncardiacsurgerystudyprotocolforamulticentricopenlabelrandomisedcon AT mariappanramamani effectofcontinuingversuswithholdingangiotensinconvertingenzymeinhibitorsangiotensiniireceptorblockersonmortalityandmajoradversecardiovasculareventsinhypertensivepatientsundergoingelectivenoncardiacsurgerystudyprotocolforamulticentricopenlabelrandomisedcon AT chandytonythomson effectofcontinuingversuswithholdingangiotensinconvertingenzymeinhibitorsangiotensiniireceptorblockersonmortalityandmajoradversecardiovasculareventsinhypertensivepatientsundergoingelectivenoncardiacsurgerystudyprotocolforamulticentricopenlabelrandomisedcon AT effectofcontinuingversuswithholdingangiotensinconvertingenzymeinhibitorsangiotensiniireceptorblockersonmortalityandmajoradversecardiovasculareventsinhypertensivepatientsundergoingelectivenoncardiacsurgerystudyprotocolforamulticentricopenlabelrandomisedcon |